Minerva Group Holding Limited Announces Non-Underwritten Rights Issue to Raise Up to HK\$43.3 Million
Key Highlights
- Rights Issue: One (1) Rights Share for every two (2) existing Shares at HK\$0.038 per Rights Share
- Potential Fundraising: Up to HK\$43.3 million (before expenses), with estimated net proceeds of HK\$41.5 million
- Non-Underwritten: The Rights Issue is not underwritten; subscription is at the discretion of shareholders
- Timeline: Acceptance and payment deadline is 4:00 p.m., 22 June 2026; Rights Shares expected to be listed on 21 July 2026
- Purpose: To strengthen capital base, support margin financing, expand business scope (including U.S. equities and tokenised securities), and support money lending and asset investments
- Potential Shareholder Impact: Shareholders who do not participate will be diluted; all shareholders have equal opportunity to participate or sell nil-paid rights in the market
- Risk Warning: The Rights Issue is subject to key conditions and may not proceed if not fulfilled
Detailed Article
Introduction
Minerva Group Holding Limited (HKEX Stock Code: 397) has announced a significant non-underwritten Rights Issue, aiming to raise up to HK\$43.3 million before expenses. This move is designed to bolster the Company’s capital position and support its strategic expansion plans, particularly in margin financing, U.S. equities, tokenised securities activities, and its money lending and asset investment businesses.
Rights Issue Structure
- Basis: Eligible shareholders will be offered one (1) Rights Share for every two (2) existing shares held as of the Record Date (4 June 2026).
- Subscription Price: HK\$0.038 per Rights Share, representing a discount to recent market prices and net asset value.
- Maximum Shares Issued: Up to 1,140,946,367 Rights Shares (assuming no new shares are issued or repurchased before the Record Date).
- Enlarged Share Capital: Upon full subscription, total issued shares will increase to 3,422,839,101.
- Non-Underwritten: There is no minimum subscription level. Any Rights Shares not taken up will be placed via a Placing Agent or remain unsubscribed.
- Trading of Rights: Nil-paid Rights Shares can be traded on the Stock Exchange between 9 June 2026 and 16 June 2026. Shareholders can renounce or sell their Rights if they do not wish to subscribe.
Use of Proceeds and Strategic Rationale
- 60% of Net Proceeds: Targeted for expanding the Group’s financial services business, mainly margin financing to clients. The Group notes that over 90% of its liquid assets are already committed to margin financing, with limited headroom under regulatory capital requirements.
- 10%: For upgrading and enhancing the Group’s financial trading system and infrastructure, supporting planned expansion into U.S. equities dealing and tokenised securities-related business, subject to regulatory approval.
- 20%: To provide additional capital for the Group’s money lending and asset investment segments, including legal, professional, and ongoing management costs, as well as new loan drawdowns.
- 10%: For office and administrative costs, professional and compliance-related fees, investor relations, and other business development activities.
The Company emphasizes that without this Rights Issue, its ability to expand margin financing and new business lines is severely constrained by capital adequacy rules and tight cash liquidity.
Business Outlook
Despite a robust macroeconomic recovery in Hong Kong (2025 GDP growth forecast at 3.2%, Hang Seng Index up 27.8%), Minerva’s bottom line has been pressured by a tough credit environment – with rising bankruptcies and defaults in the loan market. The Company is responding by strengthening risk controls and shifting its business mix while seeking new growth in areas such as tokenised securities and the healthcare sector.
The Group will maintain a cautious stance on new lending but plans to expand its product mix, including U.S. equities and Security Token Offerings (STOs), subject to SFC approval.
Shareholder Considerations and Risks
- Potential Dilution: Shareholders who do not take up their Rights Shares will experience dilution; those who do participate can maintain their pro-rata stake.
- Non-Underwritten Risk: As the Rights Issue is not underwritten, if there is low take-up, the final amount raised may be significantly less than the maximum, potentially impacting the Company’s ability to execute its growth plans.
- Conditions Precedent: The Rights Issue is subject to completion of several conditions, including regulatory approvals. If not all are met by 7 July 2026, the Rights Issue will not proceed.
- Market Price Sensitivity: The theoretical dilution effect is 6.9%, below the 25% Listing Rule threshold, but the Rights Issue price is at a substantial discount to net asset value.
- No Previous Fundraising: The Company has not conducted other equity fundraisings in the past 12 months and currently has no intention to do so immediately after the Rights Issue, barring significant changes in circumstances.
Important Dates
- Record Date: 4 June 2026
- Posting of Prospectus: 5 June 2026
- Nil-paid Rights Trading: 9 – 16 June 2026
- Latest Acceptance Date: 4:00 p.m., 22 June 2026
- Announcement of Results: 17 July 2026
- Listing of Fully-Paid Rights Shares: 21 July 2026
Corporate Information
Minerva Group’s principal businesses include financial services (securities brokerage, margin financing, corporate finance advisory), money lending, and asset investment. The Group is regulated by the SFC and operates in a competitive, highly regulated environment. The Company’s financials are publicly available and the latest audited net asset value per share is HK\$0.462 (as of 31 December 2025).
Conclusion
This Rights Issue is a material event for Minerva Group and its shareholders, providing a chance for capital injection at a discount but also exposing non-participating shareholders to dilution. The outcome will have a direct impact on the Company’s capital structure, growth capacity, and future business mix. Investors should pay close attention to the acceptance level, take-up by major shareholders, and the Company’s progress in expanding its regulated business lines, as these could meaningfully affect Minerva’s share price and valuation in the coming months.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should consult their professional advisers and review the full Prospectus before making any investment decision. Past performance is not indicative of future results, and all investments carry risk, including the potential loss of principal.
美利華集團控股有限公司宣佈非包銷供股集資最多4,330萬港元
重點摘要
- 供股安排：每持有兩股現有股份可獲一股供股股份，供股價每股\$0.038
- 最高集資：最多4,330萬港元（未扣除開支），預計淨籌約4,150萬港元
- 非包銷：供股並無包銷，認購與否全由股東自行決定
- 重要日程：認購及繳款截止日期為2026年6月22日下午4時，供股股份預計於2026年7月21日上市
- 用途：加強資本基礎，支持孖展融資業務，拓展新產品如美股及代幣化證券，及支持放債及資產投資業務
- 對股東之影響：未參與供股者會被攤薄，所有股東均可選擇認購或於市場出售未繳股權
- 風險提示：供股須符合多項條件，如未能達成，供股將不會進行
詳盡新聞稿
簡介
美利華集團控股有限公司（港交所編號：397）宣佈進行非包銷供股，目標集資最多4,330萬港元（未扣開支），務求加強資本實力，支持集團於孖展融資、美股及代幣化證券等新業務領域的發展，以及放債和資產投資分部的擴展。
供股詳情
- 基準：合資格股東可於登記日（2026年6月4日）每持兩股現有股份獲發一股供股股份。
- 供股價：每股\$0.038，較近期市價及資產淨值有折讓。
- 最高發行股份：最多1,140,946,367股（假設登記日前無新發行或回購股份）。
- 擴大後股本：如全數認購，總發行股份將增至3,422,839,101股。
- 非包銷：無最低認購限額，未獲認購股份將委託配售代理配售或成為未認購股份。
- 權利買賣：未繳股權可於2026年6月9日至6月16日於聯交所買賣，股東可放棄或出售權利。
資金用途及戰略考慮
- 約60%淨籌：擬用於擴展金融服務業務，尤以孖展融資為主。現時超過90%流動資產已用於孖展融資，資本充裕度有限。
- 10%：升級及強化金融交易系統及基建，支持美股、代幣化證券等新業務拓展（須監管批准）。
- 20%：增撥資本予放債及資產投資分部，包括法律、專業及日常管理開支及新放款。
- 10%：作辦公、行政、專業、合規、投資者關係及其他業務發展用途。
集團強調，如未能通過供股集資，擴展孖展及新業務能力將受限於資本規定及現金流緊張。
業務展望
雖然本港2025年經濟顯著復甦（GDP增長3.2%，恒指升27.8%），但信貸環境嚴峻，破產及違約增加，拖累集團業績。集團正加強風險管控，並藉供股拓展新產品（如代幣化證券、醫療行業），同時保持審慎。
集團將維持審慎放貸策略，並計劃拓展美股及STO（證券型代幣發行）等業務（須SFC批准）。
股東須知及風險
- 股權攤薄：未行使供股權者將被攤薄，參與者可維持原有持股比例。
- 非包銷風險：如認購不足，實際集資金額或遠低於上限，影響集團執行增長計劃。
- 先決條件：供股須獲多項批准，如未能於2026年7月7日前完成，供股將告吹。
- 股價敏感：理論攤薄效應為6.9%，低於25%規則門檻，但供股價較資產淨值有大幅折讓。
- 無近期集資：過去12個月未有其他集資，完成供股後暫無即時再集資計劃，除非出現重大變化。
重要日程
- 登記日：2026年6月4日
- 寄發供股章程：2026年6月5日
- 未繳股權買賣：2026年6月9日至16日
- 認購截止：2026年6月22日下午4時
- 公佈結果：2026年7月17日
- 供股股份上市：2026年7月21日
公司資料
美利華集團主要業務為金融服務（證券經紀、孖展、企業融資顧問）、放債及資產投資。集團受證監會監管，處於競爭激烈及高度規管市場。最新每股資產淨值為\$0.462（2025年12月31日止）。
總結
是次供股為美利華集團及其股東重大事件，既提供低價增資機會，亦令未參與者面臨攤薄。供股結果、主要股東動向及集團新業務推展進度，將直接影響公司資本結構、增長能力及未來業務組合，並可能左右短中期股價及估值。投資者應密切關注。
免責聲明
本文僅供參考，並不構成任何投資建議。投資者應細閱供股章程及諮詢專業顧問，方作投資決定。過往表現不代表未來，所有投資均有風險，包括本金損失。
